In this episode we discuss:
- Your background
- Overview of FibroBiologics
- Their fibroblast technology platform and its therapeutic potential
- What his formula has been for growing and scaling the team and product pipeline
- Key takeaways from #BIO2023
- What trends do he sees developing right now in regenerative medicine that will continue through the end of 2023
- What’s next?
Watch
Listen
Read
Introduction
Jared S. Taylor welcomes listeners to the Bio Breakthroughs podcast and introduces Pete O’Heeron, the esteemed founder and CEO of FibroBiologics.
Unveiling the Journey
Pete O’Heeron shares insights into his background in hospital administration, his passion for working with innovative doctors, and how he identified the need to take medical inventions across the finish line.
From Invention to FibroBiologics
Discover how Pete’s team at FibroBiologics transformed a revolutionary surgical instrument project into a game-changing venture through strategic financing and exceptional dedication.
The Power of Fibroblast Technology
Unravel the remarkable therapeutic potential of fibroblast cells, which outnumber stem cells in the human body. Learn how they are easier to harvest, more potent, and hold immense promise for regenerative medicine.
Financing the Future
Explore the unique financing mechanism employed by FibroBiologics, driven by angel investors and neurosurgeons, that has enabled them to explore various scientific avenues in fibroblast research.
The Landscape of Regenerative Medicine
Gain insights into the emerging trends in regenerative medicine, including the anticipation of FDA approval for cell therapy, as well as exciting developments in immunotherapy and gene therapy.
A Glimpse into the Future
Discover FibroBiologics’ plans for the future, with expanding human trials, an ever-growing research team, and potential public offering, as they continue their quest to revolutionize medicine.
Shaping the Cure
Explore the revolutionary perspective on curing chronic diseases with regenerative therapies, debunking traditional chemical compounds in favor of cell therapy, immunotherapy, and gene therapy.
Closing Thoughts
Jared S. Taylor extends his gratitude to Pete O’Heeron for sharing his invaluable insights on the Bio Breakthroughs podcast, hinting at future discussions on stem cells and fibroblast technology.
WORD FROM OUR SPONSORS:
Our sponsor for this episode are Sage Growth Partners.
Sage Growth Partners accelerates commercial success for healthcare organizations through a singular focus on growth. The company helps its clients thrive amid the complexities of a rapidly changing marketplace with deep domain expertise and an integrated application of research, strategy, and marketing. For more information, please go to www.sage-growth.com & follow Sage Growth Partners on social media – @sagegrowthpartners
Learn more about FibroBiologics follow these links:
– LinkedIn – Website –
Also, be sure to follow Slice of Healthcare on our social channels:
– Website – LinkedIn – Twitter – YouTube – Newsletter –
